Azamian Bobak R. 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 19, 2024
Insider Transaction Report
Form 4
Azamian Bobak R.
DirectorPresident/CEO and Board Chair
Transactions
- Exercise/Conversion
Common Stock
2024-03-15+28,274→ 36,871 total - Sale
Common Stock
2024-03-18$30.60/sh−10,415$318,699→ 26,456 total - Exercise/Conversion
Restricted Stock Units
2024-03-15−11,299→ 22,599 total→ Common Stock (11,299 underlying) - Exercise/Conversion
Restricted Stock Units
2024-03-15−16,975→ 50,925 total→ Common Stock (16,975 underlying)
Holdings
- 830,106(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
- [F4]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F5]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.
- [F6]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service.